Sun Pharma Advanced Research Company Limited (SPARC) has announced its audited standalone financial results for the quarter and year ended March 31, 2026. The company reported a substantial increase in financial performance, primarily attributed to the recognition of revenue from the sale of a Priority Review Voucher (PRV) for Sezaby®. The following table presents the comparative analysis of revenue and profit for the current quarter (Q4 FY26) against the previous quarter (Q3 FY26) and the corresponding quarter of the previous year (Q4 FY25).

Export to Sheets

Sun Pharma Advanced Research Company Limited (SPARC) is a clinical-stage bio-pharmaceutical company based in Mumbai, India, that focuses on the research and development of innovative therapeutics and drug delivery systems. Founded in 2006, the company operates with a commitment to improving standards of care for patients globally through advancements in novel drug delivery systems (NDDS) and new chemical entities (NCEs). In 2025, the company prioritized its clinical assets, such as SCD-153 and SBO-154, and adopted a more flexible business model, including the formation of asset-specific subsidiaries like Genokine Biotech, which was incorporated in July 2025. Additionally, the company made headlines in late 2025 for securing a favorable court ruling regarding its Sezaby PRV and successfully entering into a definitive asset purchase agreement to sell said voucher for USD 195 million. The company’s shareholding is prominently held by the promoter group, including Shanghvi Finance Private Limited, which held approximately 43.79% of shares as of December 2025.